Literature DB >> 25655919

Hypotensive and sympathoinhibitory responses to selective central AT2 receptor stimulation in spontaneously hypertensive rats.

Sofie Brouwers1, Ilse Smolders2, Richard D Wainford3, Alain G Dupont2.   

Abstract

The type 2 angiotensin receptor (AT2R) has been suggested to counterbalance the type 1 angiotensin receptor (AT1R) in the central regulation of blood pressure and sympathetic tone. In the present study we investigated the blood pressure responses to stimulation of central AT2Rs by the selective agonist Compound 21 in conscious spontaneously hypertensive rats (SHRs) and normotensive Wistar Kyoto rats (WKY rats). We also assessed the impact on noradrenaline [norepinephrine (NE)] plasma levels, autonomic function, spontaneous baroreflex sensitivity, and the possible involvement of the nitric oxide (NO) pathway and the AT1Rs. Chronic intracerebroventricular Compound 21 infusion lowered blood pressure and NE plasma levels in both rat strains. The night-time hypotensive effect was greater in SHRs compared with WKY rats. Compound 21 improved spontaneous baroreflex sensitivity more in SHRs than in WKY rats. These effects were abolished by co-administration of the AT2R antagonist PD123319 or the NO synthase inhibitor Nω-nitro-L-arginine methyl ester hydrochloride (L-NAME). Central AT1R blockade did not enhance the hypotensive response to Compound 21. Chronic selective stimulation of central AT2Rs lowers blood pressure through sympathoinhibition, and improves spontaneous baroreflex sensitivity more in SHRs than in WKY rats. These responses appear to require a functioning central NO pathway, but are not modified by central AT1R blockade. Collectively, the data demonstrate specific beneficial effects of stimulation of central AT2Rs in hypertension associated with increased sympathetic tone, and suggest that central AT2Rs may represent a potential new therapeutic target for the treatment of neurogenic hypertension.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25655919      PMCID: PMC4430196          DOI: 10.1042/CS20140776

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  47 in total

1.  Role of bradykinins and nitric oxide in the AT2 receptor-mediated hypotension.

Authors:  B Sosa-Canache; M Cierco; C I Gutierrez; A Israel
Journal:  J Hum Hypertens       Date:  2000-04       Impact factor: 3.012

Review 2.  Brain angiotensin peptides regulate sympathetic tone and blood pressure.

Authors:  Alain G Dupont; Sofie Brouwers
Journal:  J Hypertens       Date:  2010-08       Impact factor: 4.844

3.  Role of AT2 receptor in the brain in regulation of blood pressure and water intake.

Authors:  Zhen Li; Masaru Iwai; Lan Wu; Tetsuya Shiuchi; Toyohisa Jinno; Tai-Xing Cui; Masatsugu Horiuchi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-09-05       Impact factor: 4.733

4.  Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor.

Authors:  H M Siragy; T Inagami; T Ichiki; R M Carey
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

5.  Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist.

Authors:  Yiqian Wan; Charlotta Wallinder; Bianca Plouffe; Hélène Beaudry; A K Mahalingam; Xiongyu Wu; Berndt Johansson; Mathias Holm; Milad Botoros; Anders Karlén; Anders Pettersson; Fred Nyberg; Lars Fändriks; Nicole Gallo-Payet; Anders Hallberg; Mathias Alterman
Journal:  J Med Chem       Date:  2004-11-18       Impact factor: 7.446

6.  Stimulation of angiotensin AT2 receptors by the non-peptide agonist, Compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats.

Authors:  S Bosnyak; I K Welungoda; A Hallberg; M Alterman; R E Widdop; E S Jones
Journal:  Br J Pharmacol       Date:  2010-01-28       Impact factor: 8.739

Review 7.  Angiotensin II type-2 receptor-specific effects on the cardiovascular system.

Authors:  Ying Li; Xiao-Hui Li; Hong Yuan
Journal:  Cardiovasc Diagn Ther       Date:  2012-03

8.  AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR.

Authors:  Xiao C Li; Robert E Widdop
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

9.  Chronic absence of baroreceptor inputs prevents training-induced cardiovascular adjustments in normotensive and spontaneously hypertensive rats.

Authors:  Alexandre Ceroni; Laiali J Chaar; Rafael L Bombein; Lisete C Michelini
Journal:  Exp Physiol       Date:  2009-02-27       Impact factor: 2.969

10.  Effects of angiotensin type 2 receptor overexpression in the rostral ventrolateral medulla on blood pressure and urine excretion in normal rats.

Authors:  Lie Gao; Weizhong Wang; Wei Wang; Hongwei Li; Colin Sumners; Irving H Zucker
Journal:  Hypertension       Date:  2007-12-17       Impact factor: 10.190

View more
  17 in total

Review 1.  Centrally Mediated Cardiovascular Actions of the Angiotensin II Type 2 Receptor.

Authors:  U Muscha Steckelings; Annette de Kloet; Colin Sumners
Journal:  Trends Endocrinol Metab       Date:  2017-07-18       Impact factor: 12.015

Review 2.  Protective Angiotensin Type 2 Receptors in the Brain and Hypertension.

Authors:  Annette D de Kloet; Ulrike M Steckelings; Colin Sumners
Journal:  Curr Hypertens Rep       Date:  2017-06       Impact factor: 5.369

3.  Brain angiotensin type-1 and type-2 receptors: cellular locations under normal and hypertensive conditions.

Authors:  Colin Sumners; Amy Alleyne; Vermalí Rodríguez; David J Pioquinto; Jacob A Ludin; Shormista Kar; Zachary Winder; Yuma Ortiz; Meng Liu; Eric G Krause; Annette D de Kloet
Journal:  Hypertens Res       Date:  2019-12-18       Impact factor: 3.872

Review 4.  Role of neurons and glia in the CNS actions of the renin-angiotensin system in cardiovascular control.

Authors:  Annette D de Kloet; Meng Liu; Vermalí Rodríguez; Eric G Krause; Colin Sumners
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-06-17       Impact factor: 3.619

Review 5.  The Angiotensin AT2 Receptor: From a Binding Site to a Novel Therapeutic Target.

Authors:  U Muscha Steckelings; Robert E Widdop; Edward D Sturrock; Lizelle Lubbe; Tahir Hussain; Elena Kaschina; Thomas Unger; Anders Hallberg; Robert M Carey; Colin Sumners
Journal:  Pharmacol Rev       Date:  2022-10       Impact factor: 18.923

6.  Angiotensin Type-2 Receptors Influence the Activity of Vasopressin Neurons in the Paraventricular Nucleus of the Hypothalamus in Male Mice.

Authors:  Annette D de Kloet; Soledad Pitra; Lei Wang; Helmut Hiller; David J Pioquinto; Justin A Smith; Colin Sumners; Javier E Stern; Eric G Krause
Journal:  Endocrinology       Date:  2016-06-06       Impact factor: 4.736

Review 7.  Brain Angiotensin Type-1 and Type-2 Receptors in Physiological and Hypertensive Conditions: Focus on Neuroinflammation.

Authors:  Khalid Elsaafien; Annette D de Kloet; Eric G Krause; Colin Sumners
Journal:  Curr Hypertens Rep       Date:  2020-07-13       Impact factor: 5.369

8.  Central Infusion of Angiotensin II Type 2 Receptor Agonist Compound 21 Attenuates DOCA/NaCl-Induced Hypertension in Female Rats.

Authors:  Shu-Yan Dai; Yu-Ping Zhang; Wei Peng; Ying Shen; Jing-Jing He
Journal:  Oxid Med Cell Longev       Date:  2015-12-13       Impact factor: 6.543

9.  Targeting angiotensin type-2 receptors located on pressor neurons in the nucleus of the solitary tract to relieve hypertension in mice.

Authors:  Mazher Mohammed; Dominique N Johnson; Lei A Wang; Scott W Harden; Wanhui Sheng; Eliot A Spector; Khalid Elsaafien; Michael Bader; U Muscha Steckelings; Karen A Scott; Charles J Frazier; Colin Sumners; Eric G Krause; Annette D de Kloet
Journal:  Cardiovasc Res       Date:  2022-02-21       Impact factor: 13.081

Review 10.  Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders.

Authors:  Ludovit Paulis; Sébastien Foulquier; Pawel Namsolleck; Chiara Recarti; Ulrike Muscha Steckelings; Thomas Unger
Journal:  Drugs       Date:  2016-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.